Vir Biotechnology (VIR) Stock Forecast & Price Target

Vir Biotechnology is supported by a compelling two-pronged fundamental story: a de-risked hepatitis delta virus opportunity and a differentiated PRO-XTEN oncology platform. VIR-5500’s completed monotherapy dose escalation in 58 patients showed no DLTs or MTD, 82% PSA50 and 53% PSA90 at or above 3,000 µg/kg, and 45% RECIST responses, while SOLSTICE data showed HDV RNA target-not-detected rising to 88% at Week 96. With modeled 2026E revenue of $259.3 million versus $245.2 million consensus and a long runway from license rights, milestones, and future product launches, the company’s multiple near- and medium-term inflection points reinforce a constructive outlook.

Vir Biotechnology is viewed negatively because its value is still concentrated in a narrow HDV franchise and a heavily discounted pipeline, while much of the PRO-XTEN and oncology opportunity depends on late-stage success that remains unproven. The company’s current revenue base is mostly transaction-driven, with 2026E revenue of $259.3 million falling to $72.7 million in 2027E as upfronts lapse, while operating losses remain substantial even as R&D declines from $500.7 million in 2026E to $270.7 million in 2030E. Its outlook is further weakened by clinical, regulatory, reimbursement, and dilution risks, including expected annual gross equity raises of $300 million to $350 million from 2028E-2029E and growing competition in HDV.